Galectin-3蛋白在人膀胱移行细胞癌诊断中的应用价值

目的探讨Galectin-3蛋白在人膀胱移行细胞癌诊断中的应用价值。 方法收集2015年1月至2018年1月就诊于山东宁阳县第一人民医院泌尿外科接受经尿道电切术治疗的膀胱移行细胞癌患者84例，所有患者符合世界卫生组织中泌尿系统肿瘤病理学和诊断学的标准。采用免疫组织化学法检测Galectin-3蛋白的表达阳性率，比较分析Galectin-3蛋白在膀胱移行细胞癌组织中表达阳性率，及在不同病理分级、临床分期、初发以及复发肿瘤中表达阳性率的差异。 结果Galectin-3蛋白在膀胱移行细胞癌组织的表达阳性率(66.67%，56/84)明显高于癌旁组织的表达阳性率(7.69%，4/52)(χ²＝17.65，P<0.01)；病理分级为G2(68.75%，22/32)和G3级(94.12%，16/17)的低分化膀胱移行细胞癌的Galectin-3蛋白表达阳性率明显高于病理分级为G1级(42.86%，15/35)的高分化膀胱移行细胞癌组织的表达(χ²＝2.39，P<0.05)；Galectin-3蛋白的表达阳性率随着临床分期的增高而增高，在临床分期为T3期时高达100.00%(12/12)(χ²＝10.44，P<0.01)；Galectin-3蛋白在复发膀胱移行细胞癌组织的表达阳性率(69.23%，18/26)高于初发膀胱移行细胞癌组织(62.07%，36/58)，两组比较差异无统计学意义(χ²＝0.35，P>0.05)。 结论Galectin-3可作为诊断膀胱移行细胞癌和评估严重程度的生物标志物。

The value of Galectin-3 protein in the diagnosis of human bladder transitional cell carcinoma

ObjectiveTo investigate the value of Galectin-3 in the diagnosis of human bladder transitional cell carcinoma (TCC). MethodsGalectin-3 was detected by immunohistochemistry in bladder TCC patients (n=84) who underwent transurethral resection from urology department, the First People′s Hospital of Ningyang County from January 2015 to January 2018. To analyze and compare the expression of Galectin-3 in bladder TCC and its role in pathological grading, clinical staging, initial occurrence and recurrence. ResultsThe positive expression rate of Galectin-3 protein in bladder TCC was 66.67%(56/84), which was significantly higher than that in adjacent tissues (7.69%, 4/52) (χ²=17.65, P<0.01). The expression rates of Galectin-3 protein in poorly differentiated TCC of bladder (grade G2: 68.75%, 22/32, grade G3: 94.12%, 16/17) were significantly higher than that in well differentiated TCC of bladder (grade G1: 42.86%, 15/35) (χ²=2.39, P<0.05). The positive expression rate of Galectin-3 protein increased with the increase of clinical stage and reached 100%(12/12) (χ²=10.44, P<0.01) when the clinical stage was T3. The expression of Galectin-3 protein in recurrent bladder TCC (69.23%, 18/26) was higher than that in primary bladder TCC, but there was no significant difference (62.07%, 36/58) (χ²=0.35, P>0.05). ConclusionGalectin-3 can be used as a biomarker for the diagnosis and severity assessment of bladder TCC.